ORX: Orexo AB (publ) - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Orexo AB (publ)

SWE:ORX

SummaryFactSheetFinancial
Price
kr19.92
Loss Chance
54.1%
2.01JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Pharmaceuticals
9 / 14
Health Care
79 / 107
Sweden
?
530 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Camurus AB (publ)
SWE:CAMX
6.20
kr525.50
170.39%
Cinclus Pharma Holding AB (publ)
SWE:CINPHA
2.06
kr12.14
100.00%
Corline Biomedical AB
SWE:CLBIO
1.77
kr18.20
100.00%
Enzymatica AB (publ)
SWE:ENZY
2.86
kr2.43
100.00%
IRLAB Therapeutics AB (publ)
SWE:IRLAB A
0.71
kr1.26
100.00%
Jitta Factors
Growth Opportunity (25)
Recent Business Performance (22)
Financial Strength (38)
Return to Shareholders (4)
Competitive Advantage (25)
Jitta Signs
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 48.08% in the last quarter (yoy)
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
2.01
100.00%
2.16
102.25%
2.89
152.39%
Pharmaceuticals
6.20
170.39%
2.06
100.00%
1.77
100.00%
COMPANY DESCRIPTION
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
www.orexo.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.